Fractyl Health Inc. (NASDAQ:GUTS) is one of the best biotech penny stocks to buy according to analysts. On December 2, Fractyl Health announced positive six-month results from its open-label REVEAL-1 ...

After three years, only about 1 in 12 individuals taking GLP-1s to treat obesity remained on the therapy, according to a Prime Therapeutics study published on June 25. Prime is owned by 19 Blue Cross ...

BARCELONA -- A rheumatology trainee who went on TikTok to find information on her own condition may have uncovered a novel and possibly tectonic approach to treating fibromyalgia, her presentation ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. People with diabetes who were taking GLP-1 ...

A new study says that people who use tirzepatide lose more weight than people who use semaglutide Getty Tirzepatide is more effective than semaglutide for weight loss, according to a new study on ...

Another win for the jab. GLP-1 drugs like Ozempic and Wegovy have been linked to a host of benefits beyond diabetes management and weight loss, from reduced dementia risk to addiction treatment. Now ...

Talk about a lucky charm. Drugs like Ozempic — which mimic the appetite-suppressing GLP-1 hormone the body naturally produces after eating — have been shown to spur weight loss as well as ease knee ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants. The historically tight-lipped Amgen execs remain judicious with ...

Aon researchers found that within two years, improved health outcomes for patients who were taking GLP-1 drugs lowers the growth rate of medical care costs. Aon looked at medical claims data for ...